Published online before print July 18, 2005, doi: 10.1161/CIRCULATIONAHA.104.499178
(Circulation. 2005;112:521-526.)
© 2005 American Heart Association, Inc.
Heart Failure |
Transendocardial Autologous Bone Marrow Mononuclear Cell Injection in Ischemic Heart Failure
Postmortem Anatomicopathologic and Immunohistochemical Findings
From the Hospital Procardiaco (H.F.R.D., S.A.S., A.L.S.S., C.T.M., J.A.R.A., R.V.C.B., C.D., H.J.F.D.), Rio de Janeiro, Brazil; the Texas Heart Institute at St. Luke’s Episcopal Hospital (E.C.P., G.V.S., J.T.W.), Houston, Tex; and the Institute of Biomedical Sciences and Clementino Fraga Filho Hospital, Federal University (C.M.T., M.-I.D.R., B.M.O.P., I.M.A., H.S.D., R.B.), Rio de Janeiro, Brazil.
Correspondence to Hans F.R. Dohmann, MD, Rua General Polidoro 192, 22080-000 Rio de Janeiro, Brazil (e-mail diretoria.cientifica{at}procardiaco.com.br), or Emerson C. Perin, MD, 6624 Fannin, Suite 2220, Houston TX 77030 (e-mail eperin@crescentb.net).
Received March 31, 2004; de novo received August 13, 2004; revision received January 28, 2005; accepted February 23, 2005.
Background— Cell-based therapies for treatment of ischemic heart disease are currently under investigation. We previously reported the results of a phase I trial of transendocardial injection of autologous bone marrow mononuclear (ABMM) cells in patients with end-stage ischemic heart disease. The current report focuses on postmortem cardiac findings from one of the treated patients, who died 11 months after cell therapy.
Methods and Results— Anatomicopathologic, morphometric, and immunocytochemical findings from the anterolateral ventricular wall (with cell therapy) were compared with findings from the interventricular septum (normal perfusion and no cell therapy) and from the inferoposterior ventricular wall (extensive scar tissue and no cell therapy). No signs of adverse events were found in the cell-injected areas. Capillary density was significantly higher (P<0.001) in the anterolateral wall than in the previously infarcted tissue in the posterior wall. The prominent vasculature of the anterolateral wall was associated with hyperplasia of pericytes, mural cells, and adventitia. Some of these cells had acquired cytoskeletal elements and contractile proteins (troponin, sarcomeric 
-actinin, actinin), as well as the morphology of cardiomyocytes, and appeared to have migrated toward adjacent bundles of cardiomyocytes.
Conclusions— Eleven months after treatment, morphological and immunocytochemical analysis of the sites of ABMM cell injection showed no abnormal cell growth or tissue lesions and suggested that an active process of angiogenesis was present in both the fibrotic cicatricial tissue and the adjacent cardiac muscle. Some of the pericytes had acquired the morphology of cardiomyocytes, suggesting long-term sequential regeneration of the cardiac vascular tree and muscle.
Key Words: angiogenesis • stem cells • heart failure • revascularization • ischemia
This article has been cited by other articles:
 |
|
 |
|
  H.-S. V. Chen, C. Kim, and M. Mercola Electrophysiological Challenges of Cell-Based Myocardial Repair Circulation, December 15, 2009; 120(24): 2496 - 2508. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Herbots, J. D'hooge, E. Eroglu, D. Thijs, J. Ganame, P. Claus, C. Dubois, K. Theunissen, J. Bogaert, J. Dens, et al. Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study Eur. Heart J., March 2, 2009; 30(6): 662 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Olivares, R. H. Costa-e-Sousa, J. P.S. Werneck-de-Castro, V. Pinho-Ribeiro, M. G. Silva, K. C. Ribeiro, E. C. Mattos, R. C.S. Goldenberg, A. C. C. de Carvalho, and M. O. Masuda Cellular cardiomyoplasty in large myocardial infarction: Can the beneficial effect be enhanced by ACE-inhibitor therapy? Eur J Heart Fail, June 1, 2007; 9(6-7): 558 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Prockop and S. D. Olson Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions Blood, April 15, 2007; 109(8): 3147 - 3151. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhang, E. Shpall, J. T. Willerson, and E. T.H. Yeh Fusion of Human Hematopoietic Progenitor Cells and Murine Cardiomyocytes Is Mediated by {alpha}4{beta}1 Integrin/Vascular Cell Adhesion Molecule-1 Interaction Circ. Res., March 16, 2007; 100(5): 693 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Smith, L. Barile, H. C. Cho, M. K. Leppo, J. M. Hare, E. Messina, A. Giacomello, M. R. Abraham, and E. Marban Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy Specimens Circulation, February 20, 2007; 115(7): 896 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. de Silva, L. F. Gutierrez, A. N. Raval, E. R. McVeigh, C. Ozturk, and R. J. Lederman X-Ray Fused With Magnetic Resonance Imaging (XFM) to Target Endomyocardial Injections: Validation in a Swine Model of Myocardial Infarction Circulation, November 28, 2006; 114(22): 2342 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ben-Dor, S. Fuchs, and R. Kornowski Potential Hazards and Technical Considerations Associated With Myocardial Cell Transplantation Protocols for Ischemic Myocardial Syndrome J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1519 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Willerson, E. T.H. Yeh, Y.-J. Geng, and E. C. Perin Blood-Derived Progenitor Cells After Recanalization of Chronic Coronary Artery Occlusions in Humans Circ. Res., October 14, 2005; 97(8): 735 - 736. [Full Text] [PDF]
|
|